Literature DB >> 22993107

Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.

Xu Steven Xu1, Min Yuan, Mats O Karlsson, Adrian Dunne, Partha Nandy, An Vermeulen.   

Abstract

Shrinkage of empirical Bayes estimates (EBEs) of posterior individual parameters in mixed-effects models has been shown to obscure the apparent correlations among random effects and relationships between random effects and covariates. Empirical quantification equations have been widely used for population pharmacokinetic/pharmacodynamic models. The objectives of this manuscript were (1) to compare the empirical equations with theoretically derived equations, (2) to investigate and confirm the influencing factor on shrinkage, and (3) to evaluate the impact of shrinkage on estimation errors of EBEs using Monte Carlo simulations. A mathematical derivation was first provided for the shrinkage in nonlinear mixed effects model. Using a linear mixed model, the simulation results demonstrated that the shrinkage estimated from the empirical equations matched those based on the theoretically derived equations. Simulations with a two-compartment pharmacokinetic model verified that shrinkage has a reversed relationship with the relative ratio of interindividual variability to residual variability. Fewer numbers of observations per subject were associated with higher amount of shrinkage, consistent with findings from previous research. The influence of sampling times appeared to be larger when fewer PK samples were collected for each individual. As expected, sample size has very limited impact on shrinkage of the PK parameters of the two-compartment model. Assessment of estimation error suggested an average 1:1 relationship between shrinkage and median estimation error of EBEs.

Mesh:

Year:  2012        PMID: 22993107      PMCID: PMC3475840          DOI: 10.1208/s12248-012-9407-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  16 in total

1.  Population modelling in drug development.

Authors:  L Sheiner; J Wakefield
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

2.  Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.

Authors:  Charlotte Kloft; Italo Poggesi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10-24       Impact factor: 4.481

Review 3.  Diagnosing model diagnostics.

Authors:  M O Karlsson; R M Savic
Journal:  Clin Pharmacol Ther       Date:  2007-07       Impact factor: 6.875

4.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

5.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

6.  Classifying individuals based on predictors of random effects. Multicenter AIDS Cohort Study.

Authors:  R H Lyles; J Xu
Journal:  Stat Med       Date:  1999-01-15       Impact factor: 2.373

7.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

8.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  18 in total

1.  Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Authors:  Thi Huyen Tram Nguyen; Thu Thuy Nguyen; France Mentré
Journal:  Pharm Res       Date:  2017-06-28       Impact factor: 4.200

2.  Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.

Authors:  Xu Steven Xu; Min Yuan; Haitao Yang; Yan Feng; Jinfeng Xu; Jose Pinheiro
Journal:  AAPS J       Date:  2016-10-19       Impact factor: 4.009

3.  Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.

Authors:  Surulivelrajan Mallayasamy; Ayyappa Chaturvedula; Michael J Fossler; Mark Sale; Vineet Goti; Namandje N Bumpus; Mark A Marzinke; Craig W Hendrix; Jessica E Haberer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.

Authors:  Sean N Avedissian; Roxane Rohani; John Bradley; Jennifer Le; Nathaniel J Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

Authors:  Ying Chen; Brian I Rini; Robert J Motzer; Janice P Dutcher; Olivier Rixe; George Wilding; Walter M Stadler; Jamal Tarazi; May Garrett; Yazdi K Pithavala
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

6.  Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Authors:  Kim Stuyckens; Fred Saad; Xu Steven Xu; Charles J Ryan; Matthew R Smith; Thomas W Griffin; Margaret K Yu; An Vermeulen; Partha Nandy; Italo Poggesi
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

7.  Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.

Authors:  Kristen Nichols; Eun Kyoung Chung; Chad A Knoderer; Lauren E Buenger; Daniel P Healy; Jennifer Dees; Ashley S Crumby; Michael B Kays
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

8.  The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.

Authors:  Betty A Maganda; Eliford Ngaimisi; Appolinary A R Kamuhabwa; Eleni Aklillu; Omary M S Minzi
Journal:  Malar J       Date:  2015-04-25       Impact factor: 2.979

9.  Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life.

Authors:  Suein Choi; Sangil Jeon; Dong-Seok Yim; Seunghoon Han
Journal:  Drug Des Devel Ther       Date:  2020-02-25       Impact factor: 4.162

10.  A population pharmacokinetic-pharmacodynamic model of YH12852, a highly selective 5-hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation.

Authors:  Siun Kim; Hyun A Lee; Seong Bok Jang; Howard Lee
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.